Benny Sorensen (COAG) discloses multiple warrant awards
Rhea-AI Filing Summary
Hemab Therapeutics Holdings, Inc. director and officer Benny Sorensen filed an initial ownership report listing several warrant positions on the company’s common stock. These include warrants exercisable at $6.00 for 980,782 underlying shares expiring on January 28, 2036 and warrants at $7.07 for 405,658 shares expiring on August 13, 2033.
Additional holdings are warrants at an exercise price of $2.16 for 251,922 underlying shares expiring on March 20, 2032 and warrants at $6.08 for 76,824 shares expiring on February 1, 2031. Footnotes state one grant from 2021 and one from 2022 are fully vested, while grants from 2023 and 2026 vest over four years with 25% cliff vesting and the remainder in equal monthly installments.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Sorensen Benny
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Warrants (Right to Buy) | -- | -- | -- |
| holding | Warrants (Right to Buy) | -- | -- | -- |
| holding | Warrants (Right to Buy) | -- | -- | -- |
| holding | Warrants (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Warrants (Right to Buy) — 1,715,186 shares (Direct)
Footnotes (4)
- F1. The warrant was granted on February 2, 2021 and is fully vested.
- F2. The warrant was granted on March 21, 2022 and is fully vested.
- F3. The warrant was granted on August 14, 2023. The shares underlying the warrant vest over four years, with 25% of the shares having vested on March 1, 2024 and the remaining shares vesting in equal monthly installments thereafter.
- F4. The warrant was granted on January 29, 2026. The shares underlying the warrant vest over four years, with 25% of the shares vesting on January 1, 2027 and the remaining shares vesting in equal monthly installments thereafter.
Key Figures
Warrant exercise price: $6.00 per share
Underlying shares: 980,782 shares
Warrant exercise price: $7.07 per share
+5 more
8 metrics
Warrant exercise price
$6.00 per share
Warrants expiring January 28, 2036; 980,782 underlying shares
Underlying shares
980,782 shares
Common stock underlying $6.00 exercise price warrants, direct ownership
Warrant exercise price
$7.07 per share
Warrants expiring August 13, 2033; 405,658 underlying shares
Underlying shares
405,658 shares
Common stock underlying $7.07 exercise price warrants, direct ownership
Warrant exercise price
$2.16 per share
Warrants expiring March 20, 2032; 251,922 underlying shares
Underlying shares
251,922 shares
Common stock underlying $2.16 exercise price warrants, direct ownership
Warrant exercise price
$6.08 per share
Warrants expiring February 1, 2031; 76,824 underlying shares
Underlying shares
76,824 shares
Common stock underlying $6.08 exercise price warrants, direct ownership
Key Terms
Warrants (Right to Buy), exercise price, expiration date, fully vested, +1 more
5 terms
Warrants (Right to Buy) financial
"security_title: Warrants (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 6.0000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-01-28T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
fully vested financial
"The warrant was granted on February 2, 2021 and is fully vested."
vesting in equal monthly installments financial
"the remaining shares vesting in equal monthly installments thereafter."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does Hemab Therapeutics (COAG) director Benny Sorensen report on this Form 3?
Benny Sorensen reports initial holdings of several warrants on Hemab Therapeutics common stock. These positions give rights to buy shares at fixed exercise prices before stated expiration dates, with some grants fully vested and others vesting over four years.
What are the main warrant positions reported by Benny Sorensen at Hemab Therapeutics (COAG)?
Sorensen reports warrants with an exercise price of $6.00 covering 980,782 underlying common shares and warrants at $7.07 covering 405,658 shares. He also holds warrants at $2.16 for 251,922 shares and $6.08 for 76,824 shares, each with specific expiration dates.
When do Benny Sorensen’s reported Hemab Therapeutics (COAG) warrants expire?
The reported warrants expire on several future dates: January 28, 2036 for the $6.00 series, August 13, 2033 for the $7.07 series, March 20, 2032 for the $2.16 series, and February 1, 2031 for the $6.08 series, as disclosed in the filing.
How do the vesting terms work for Benny Sorensen’s Hemab Therapeutics (COAG) warrants?
Footnotes state the 2021 and 2022 warrant grants are fully vested. The 2023 grant vests over four years, with 25% vested on March 1, 2024 and the rest vesting in equal monthly installments. The 2026 grant follows a similar four-year schedule starting January 1, 2027.
Does this Hemab Therapeutics (COAG) Form 3 show any insider buying or selling activity?
The Form 3 lists warrant holdings and their terms but does not show buy or sell transactions. Transaction codes are marked as unknown, and the transactions are categorized as holdings, reflecting positions rather than recent market trades.